Valo SPAC Presentation Deck
Opal platform offers the opportunity to accelerate the development of
programs
OPAL PLATFORM
New target identification in weeks
(CV and ND targets discovered and/or statistically
validated in less than a month)
New molecule identification, validation and
transition to hit-to-leads (H2L) in months
(H2L 1 billion evaluated, 100s made/tested, multiple
proprietary series)
Lead optimization (LO) in months
(LO in 9-12 months driven by Opal-enabled compressed number
of LO chemistry cycles)
Causal biomarker discovery in months
(0 to novel Parkinson's biomarker in 2 months)
VS.
VS.
VS.
VS.
INDUSTRY
6-12 months for typical target discovery using
surrogates rather than humans¹
Average of 6-12 months to move from target to
hit to lead candidate¹
Average of two years spent in lead
optimization alone¹
Significant time and resource investment to
discover clinically relevant biomarkers²
CV = cardiovascular; ND = neurodegenerative; H2L = hit-to-lead; LO = lead optimization
Valo [1] Paul, Steven M., et al. "How to improve R&D productivity: the pharmaceutical industry's grand challenge." Nat Rev Drug Discov 9, 203-214 (Mar 2010). [2] See, for example, Paulovich, Amanda G., et al.
interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline." Proteomics Clin Appl 2, 1386-1402 (Oct 2008).
"The
2Q21
24View entire presentation